KCTV: Saint Luke's Study Finds GLP-1 Medications May Improve Addictive Behaviors

Researchers at Saint Luke’s Mid America Heart Institute are sharing the latest results of an observational study that revealed weight loss medications may be effective in addressing addictive behaviors like recreational drug use, alcohol consumption, and food cravings.

Dr. James O’Keefe, a co-investigator of this study and director of preventive cardiology at the Mid America Heart Institute, talked with KCTV about the possible new benefits of GLP-1 receptor agonists like Ozempic®.

Related Content

Feb. 24, 2025

GLP-1 Medications Associated with Improving Addictive Behaviors
Dr. James O’Keefe, a co-investigator of this study, explains why GLP-1 medications may be uniquely effective in addressing addictive behaviors like recreational drug use, alcohol consumption, and food cravings.
Aug. 25, 2023

U.S. News & World Report: Wegovy May Be Valuable New Option for Heart Failure Patients
Weight-loss drug Wegovy (semaglutide) and its diabetes-focused cousin, Ozempic, have already upended the treatment of both obesity and diabetes, with sales of both drugs skyrocketing.
Feb. 18, 2025

Health Central: Should You Take Ozempic if You Have MS?
Growing research shows why popular GLP-1 weight loss medications might be beneficial for people with multiple sclerosis, but the jury’s still out.